We're always working to initiate change for patients
This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.
UroGen® profile
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.
Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Our leadership
News releases
May 12, 2025
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025 ; assuming approval, commercial launch to immediately follow with product availability in July Oncologic Drugs Advisory Committee scheduled for May 21, 2025 JELMYTO ® achieved net product sales of $20.3
Read storyMay 7, 2025
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J. --(BUSINESS WIRE)--May 7, 2025-- UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Oncologic Drugs
Read storyMay 1, 2025
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Conference Call and Webcast Scheduled for Monday, May 12, 2025 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
Read story